Survivin Antibody, anti-human, REAfinity™
Synonyms: BIRC5, API4, IAP4
RECOMBINANT
Clone:
REA1546 | J.33.5
Type of antibody:
Recombinant antibodies, Primary antibodies
Isotype:
recombinant human IgG1
Applications:
MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »

Related products for Survivin Antibody, anti-human, REAfinity™

MICS (MACSima Imaging Cyclic Staining) applications
PE
Fixation:
frozen – PFA
Species tested:
human
Tissue used:
breast cancer
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-141-919
Testing grade:
** Qualified
Description:
Immunofluorescence analysis of a human breast cancer cryosection fixed with 4% PFA. The section was stained using Survivin Antibody, anti-human, PE (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Fixation:
FFPE
Species tested:
human
Tissue used:
breast cancer
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-141-919
Testing grade:
** Qualified
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin embedded (FFPE) human breast cancer. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using Survivin Antibody, anti-human, PE (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Specifications for Survivin Antibody, anti-human, REAfinity™
Overview

Clone REA1546 recognizes the human Survivin antigen, a member of the inhibitor of apoptosis (IAP) family. Survivin is also known as baculoviral IAP repeat-containing protein 5 (BIRC5) or apoptosis inhibitor 4 (API4). The survivin protein inhibits caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. Expression of survivin is highly regulated by the cell cycle and is only expressed in the G2-M phase. Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. It is expressed highly in most human tumors and fetal tissue, but is completely absent in terminally differentiated cells. Its overexpression has been demonstrated in breast and lung cancer, prostate, gastric, colon, bladder and esophageal carcinomas, osteosarcomas, and lymphomas. Overexpression of survivin was also found to be significantly associated with a poor prognosis and decreased survival rates in oral, breast and colorectal cancers.

Alternative names

BIRC5, API4, IAP4

Detailed product information

Technical specifications

Clone
REA1546
Clonality
monoclonal
Isotype
recombinant human IgG1
Host
cell line
Type of antibody
Recombinant antibodies, Primary antibodies
Species reactivity
human
Antigen
Survivin

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for Survivin Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for Survivin Antibody, anti-human, REAfinity™
Publications
  1. Cheung, A. et al. (2016) Targeting folate receptor alpha for cancer treatment. Oncotarget. 9 (32): 52553-52574
  2. Fukuda, S. et al. (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 5 (5): 1087-1098
  3. Ambrosini, G. et al. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (8): 917-921